Magnetic Resonance-guided Focused Ultrasound (MRgFUS) therapy (ExAblate; InSightec Ltd.) for ablation of uterine fibroids

Record ID 32014000491
English
Authors' recommendations: Uterine fibroids (also called leiomyomata or myomas) are benign tumors of the myometrium, the smooth muscle layer of the uterus. Most women develop fibroids. In the sixth decade of life, the prevalence of fibroids is almost 70% in Caucasian women and 80% in black women. In the United States, where the annual cost of hysterectomies exceeds $1.2 billion, fibroids are the most common indication for hysterectomy. About 25% of fibroids are symptomatic. They can produce pain, bleeding, infertility, abdominal enlargement, urinary frequency, constipation, and dyspareunia (pain during intercourse). Treatments for symptomatic fibroids include medical management, hysterectomy, myomectomy (removal of the fibroids while leaving the uterus in situ), radiofrequency ablation (RFA), uterine artery embolization (UAE), laser ablation, cryoablation, and image-guided thermal ablation. All current surgical treatments are invasive and all treatments have limitations.
Details
Project Status: Completed
Year Published: 2014
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: United States
MeSH Terms
  • Humans
  • Ultrasonic Therapy
  • Uterine Neoplasms
  • Magnetic Resonance Imaging
  • Ultrasound, High-Intensity Focused, Transrectal
Contact
Organisation Name: HAYES, Inc.
Contact Address: 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name: saleinfo@hayesinc.com
Contact Email: saleinfo@hayesinc.com
Copyright: 2014 Winifred S. Hayes, Inc
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.